Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
29
07
2019
accepted:
03
12
2019
revised:
12
11
2019
pubmed:
12
1
2020
medline:
9
7
2021
entrez:
12
1
2020
Statut:
ppublish
Résumé
The natural history of ductal carcinoma in situ (DCIS) is highly variable and difficult to predict. Biomarkers are needed to stratify patients with DCIS for adjuvant therapy. We investigated the prognostic and predictive relevance of cell cycle progression (CCP) score in women with DCIS. We measured the expression of 23 genes involved in CCP with quantitative RT-PCR on RNA extracted from formalin-fixed paraffin-embedded tumor samples, and assessed the correlation of a predefined score with histopathologic features and recurrence. The signature was analyzed in a cohort of 909 consecutive DCIS with full histopathological features treated in a single institution. The main outcome measure was ipsilateral breast event (IBE) as first event observed, be it in situ or invasive. Median follow-up time was 8.7 years (IQR 6.5-10.5 years). There were 150 ipsilateral IBEs, 84 (56%) of which were invasive. In the first 5 years of follow-up, the score provided statistically different findings (p = 0.009), with IBE rates of 14.7% (95% CI, 10.4-19.7) for the highest quartile of CCP score (Q4) and 8.7% (95% CI, 6.7-11.0) for the lowest quartiles (Q1-3). The prognostic value for IBEs approached significance also in women treated with mastectomy (adjusted hazard ratio [HR] Q4 vs. Q1-3 = 2.60; 95% CI: 0.96-7.08; P = 0.06). Radiotherapy provided a greater benefit in women with higher CCP score. In addition, Q4 predicted a different risk after tamoxifen depending on menopausal status, with a beneficial trend on IBEs in postmenopausal women (HR 0.30; 95% CI, 0.07-1.39), and an opposite trend in premenopausal women (HR 1.68; 95% CI, 0.38-7.44) (P-interaction = 0.03). The results of this study provide for the first time the evidence that CCP score is a prognostic marker, which, after additional validation, could have an important role in personalizing the management of DCIS.
Identifiants
pubmed: 31925342
doi: 10.1038/s41379-020-0452-0
pii: S0893-3952(22)00836-5
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1065-1077Références
National Comprehensive Cancer Network. Breast cancer version 1.2019. National Comprehensive Cancer Network. 2019. https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf .
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v8–30.
doi: 10.1093/annonc/mdv298
National Institute for Health and Care Excellence (NICE). Early and locally advanced breast cancer: diagnosis and management. National Institute for Health and Care Excellence. 2018. https://www.nice.org.uk/guidance/ng101 .
Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1:888–96.
doi: 10.1001/jamaoncol.2015.2510
Decensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol. 2019;37:1629–37
Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28:3762–9.
doi: 10.1200/JCO.2009.26.8847
Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105:701–10.
doi: 10.1093/jnci/djt067
Nofech-Mozes S, Hanna W, Rakovitch E. Molecular evaluation of breast ductal carcinoma in situ with oncotype DX DCIS. Am J Pathol. 2019;189:975–80.
doi: 10.1016/j.ajpath.2018.12.003
Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, et al. Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. Br J Cancer. 2013;108:1593–601.
doi: 10.1038/bjc.2013.147
Lazzeroni M, Dunn BK, Pruneri G, Jereczek-Fossa BA, Orecchia R, Bonanni B, et al. Adjuvant therapy in patients with ductal carcinoma in situ of the breast: the Pandora’s box. Cancer Treat Rev. 2017;55:1–9.
doi: 10.1016/j.ctrv.2017.01.010
Mosley JD, Keri RA. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genom. 2008;1:11.
doi: 10.1186/1755-8794-1-11
Starmans MH, Krishnapuram B, Steck H, Horlings H, Nuyten DS, van d V, et al. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer. 2008;99:1884–90.
doi: 10.1038/sj.bjc.6604746
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10:R65.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 2006;100:229-235.
Bueno R, Hughes E, Wagner S, Gutin AS, Lanchbury JS, Zheng Y, et al. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol. 2015;10:67–73.
doi: 10.1097/JTO.0000000000000365
Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12:245–55.
doi: 10.1016/S1470-2045(10)70295-3
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.
doi: 10.1093/annonc/mdr304
Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, et al. Cancer outcomes in DCIS patients without locoregional treatment. J Natl Cancer Inst. 2019;111:952–60.
doi: 10.1093/jnci/djy220
Leon P, Cancel-Tassin G, Drouin S, Audouin M, Varinot J, Comperat E, et al. Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy. World J Urol. 2018;36:1495–1500.
doi: 10.1007/s00345-018-2290-y
Eguchi T, Kadota K, Chaft J, Evans B, Kidd J, Tan KS, et al. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma. Oncotarget. 2016;7:35241–56.
doi: 10.18632/oncotarget.9129
Ueno D, Dancik GM, Shuch B. The cell cycle progression score: unclear role in renal cell carcinoma. Eur Urol. 2018;74:128–9.
doi: 10.1016/j.eururo.2018.03.033
Buyse M, Loi S, Van’t Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183–92.
doi: 10.1093/jnci/djj329
Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;13:3207–14.
doi: 10.1158/1078-0432.CCR-06-2765
Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, Van’t VL, et al. Comparison of prognostic gene expression signatures for breast cancer. BMC Genom. 2008;9:394.
doi: 10.1186/1471-2164-9-394
Stephen J, Murray G, Cameron DA, Thomas J, Kunkler IH, Jack W, et al. Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. Br J Cancer. 2014;111:2242–7.
doi: 10.1038/bjc.2014.530
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013;14:1067–76.
doi: 10.1016/S1470-2045(13)70387-5
Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet. 2002;360:683–9.
doi: 10.1016/S0140-6736(02)09838-0
Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, Decensi A, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019;37:3152–65.
doi: 10.1200/JCO.19.01472
Thorat MA, Wagner S, Jones LJ, Levey PM, Bulka K, Hoff R, et al. Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. Cancer Res. 2017;77 Suppl 4 :P1–09-06.
Houghton J, Baum M, Haybittle JL. Role of radiotherapy following total mastectomy in patients with early breast cancer. The Closed Trials Working Party of the CRC Breast Cancer Trials Group. World J Surg. 1994;18:117–22.
doi: 10.1007/BF00348201
O’Rourke S, Galea MH, Morgan D, Euhus D, Pinder S, Ellis IO, et al. Local recurrence after simple mastectomy. Br J Surg. 1994;8:386–9.
doi: 10.1002/bjs.1800810321
Montero-Luis A, Aristei C, Meattini I, Arenas M, Boersma L, Bourgier C, et al. The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: suggestions for routine practice. Crit Rev Oncol Hematol. 2019;138:207–13.
doi: 10.1016/j.critrevonc.2019.04.016
Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, et al. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS. Int J Cancer. 2016;139:2127–34.
doi: 10.1002/ijc.30254
Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst. 1991;83:1488–91.
doi: 10.1093/jnci/83.20.1488
Wang SY, Shamliyan T, Virnig BA, Kane R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat. 2011;127:1–14.
doi: 10.1007/s10549-011-1387-4
Solin LJ, Yeh I, Kurtz J, Fourquet A, Recht A, Kuske R, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast–conserving surgery and definitive irradiation correlation of pathologic parameters with outcome of treatment. Cancer. 1993;71:2532–42.
doi: 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0